Sutro Biopharma (STRO) Short term Debt (2017 - 2023)

Sutro Biopharma has disclosed Short term Debt across 6 years of filings, most recently posting $4.1 million for Q4 2023.

• Short term Debt for Q4 2023 came in at $4.1 million, down 67.51% year-over-year; the trailing twelve-month figure through Dec 2023 was $4.1 million (down 67.51% YoY), and the FY2023 annual result was $4.1 million, down 67.51% from the prior year.
• Short term Debt came in at $4.1 million for Q4 2023 at Sutro Biopharma, down from $7.1 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $13.2 million in Q1 2023 to a low of $1.0 million in Q4 2019.
• The 4-year median for Short term Debt is $7.1 million (2023), against an average of $8.1 million.
• Across the five-year window, Short term Debt plunged 78.83% in 2019 and jumped 300.0% in 2022, its largest moves.
• Sutro Biopharma's Short term Debt stood at $1.0 million in 2019, then jumped by 837.5% to $9.4 million in 2021, then surged by 33.33% to $12.5 million in 2022, then plunged by 67.51% to $4.1 million in 2023.
• The last three Short term Debt figures came in at $4.1 million (Q4 2023), $7.1 million (Q3 2023), and $10.2 million (Q2 2023), per Business Quant data.